| VRTX:Vertex Pharmaceuticals Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
0.06% $0.22
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older |
|
| BusinessWire |
|
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO(R) (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. |
| Full Story → |
|
| Headline News |
|
| Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older |
| 7:10a ET February 23 '24 BusinessWire |
|
|
| Vertex to Participate in Upcoming Investor Conferences |
| 4:05p ET February 20 '24 BusinessWire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| April 26 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 25 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
0.81%
